📣 VC round data is live. Check it out!
- Public Comps
- Glaukos
Glaukos Valuation Multiples
Discover revenue and EBITDA valuation multiples for Glaukos and similar public comparables like Demant, ICON plc, Baxter International, Pro Medicus and more.
Glaukos Overview
About Glaukos
Glaukos Corp is an ophthalmic pharmaceutical and medical technology company focused on developing novel, dropless therapies and commercializing associated products for the treatment of glaucoma, corneal disorders, and retinal diseases. It has commenced commercialization activities for iDose TR, a first-of-its-kind, long-duration, intracameral procedural pharmaceutical implant designed to continuously deliver glaucoma drug therapy inside the eye for extended periods of time. The company also offer commercially a proprietary bio-activated pharmaceutical therapy for the treatment of a rare corneal disorder, keratoconus. The company has three primary commercialized micro-scale surgical device products designed to treat glaucoma: the iStent, the iStent inject W, and the iStent infinite.
Founded
1998
HQ

Employees
1.1K
Website
Financials (LTM)
EV
$8B
Valuation Multiples
Start free trialGlaukos Financials
Glaukos reported last 12-month revenue of $553M and negative EBITDA of ($900K).
In the same LTM period, Glaukos generated $464M in gross profit, ($900K) in EBITDA losses, and had net loss of ($44M).
Revenue (LTM)
Glaukos P&L
In the most recent fiscal year, Glaukos reported revenue of $507M and EBITDA of ($33M).
Glaukos is unprofitable as of last fiscal year, with gross margin of 56%, EBITDA margin of (6%), and net margin of (10%).
Financial data powered by Morningstar, Inc.
Glaukos Stock Performance
Glaukos has current market cap of $8B, and enterprise value of $8B.
Market Cap Evolution
Glaukos' stock price is $142.15.
Glaukos share price decreased by 1.1% in the last 30 days, and increased by 50.8% in the last year.
Glaukos has an EPS (earnings per share) of $-0.88.
| EV | Market Cap | Price 1D | Price 1M | Price 3M | Price 12M | EPS |
|---|---|---|---|---|---|---|
| $8B | $8B | 3.5% | -1.1% | 18.1% | 50.8% | $-0.88 |
Benchmark Trading Valuation Multiples by Industry
Sign up to access valuation multiples like growth-adjusted P/E, Rule of 40, next 12-month EV/Revenue, EBITDA multiples by industry, consensus analyst estimates and many more.
Start Free TrialGlaukos Valuation Multiples
Glaukos trades at 14.8x EV/Revenue multiple, and (9078.8x) EV/EBITDA.
EV / Revenue (LTM)
Glaukos Financial Valuation Multiples
As of May 15, 2026, Glaukos has market cap of $8B and EV of $8B.
Glaukos has a P/E ratio of (190.8x).
Multiples above and below 250x are considered non-meaningful (n/m). Valuation data powered by FactSet, Inc. and Morningstar, Inc.
Verified Glaukos Valuation Multiples
Access all public comps and forward-looking valuation multiples like EV/Revenue in 2027, based on consensus analyst estimates. Powered by FactSet and Morningstar.


Glaukos Margins & Growth Rates
Glaukos grew revenue by 24% but EBITDA decreased by 263% in the last fiscal year.
In the most recent fiscal year, Glaukos reported gross margin of 56%, EBITDA margin of (6%), and net margin of (10%).
Glaukos Margins
Glaukos Growth Rates
Data powered by FactSet, Inc. and Morningstar, Inc.
Glaukos Operational KPIs
Glaukos' revenue per employee in the last FY averaged $0.5M, while opex per employee averaged $0.4M for the same period.
Glaukos' Rule of 40 is 33% (metric relevant for SaaS companies only, counted as combined revenue growth rate and EBITDA margin).
Glaukos' Rule of X is 69% (created by Bessemer, Rule of X is another metric to measure SaaS companies, ~1.5x stronger vs. the traditional Rule of 40, counted as revenue growth rate multiplied by 2.5 plus EBITDA margin).
Data powered by FactSet, Inc. and Morningstar, Inc.
Glaukos Competitors
Glaukos competitors include Demant, ICON plc, Baxter International, Pro Medicus, Masimo, Bruker, Bio-Rad Laboratories, Horiba, Insulet and Shimadzu.
Most Glaukos public comparables operate across Medical Devices, Healthcare Software, BioTech, B2B SaaS, Vertical SaaS, HealthTech and Longevity.
| EV/Revenue | EV/EBITDA | |||||
|---|---|---|---|---|---|---|
| Last FY | LTM | 2027E | Last FY | LTM | 2027E | |
| 3.0x | 2.9x | 12.6x | 12.2x | |||
| 1.4x | 1.5x | 7.7x | 8.1x | |||
| 1.5x | 1.5x | 7.4x | 7.6x | |||
| 58.6x | 49.3x | 75.7x | 55.0x | |||
| 6.0x | 6.2x | 20.4x | 20.8x | |||
| 2.4x | 2.4x | 15.4x | 14.2x | |||
| 2.5x | 2.5x | 5.4x | 14.5x | |||
| 2.7x | 2.7x | 13.6x | 13.2x | |||
This data is available for Pro users. Sign up to see all Glaukos competitors and their valuation data. Start Free Trial | ||||||
Glaukos Funding History
Before going public, Glaukos raised $30M in total equity funding, across 1 round.
Glaukos Funding Rounds
Glaukos M&A Activity
Glaukos has acquired 2 companies to date.
Last acquisition by Glaukos was on August 7th 2019. Glaukos acquired Avedro for $620M (EV/Revenue multiple of ).
Latest Acquisitions by Glaukos
| Description | Avedro is a Massachusetts-headquartered medical device company advancing corneal cross-linking technologies for keratoconus and ectasia treatments. The firm commercializes VibeX pharmaceutical and KXL System outside the US, while developing thermo-biomechanics platforms like Keraflex for non-invasive refractive corrections preserving corneal integrity. | DOSE Medical Corp. is a biotechnology company advancing bioerodible implants for sustained intraocular drug delivery. Targeting retinal conditions like wet age-related macular degeneration and diabetic macular edema, its micro-invasive platforms release therapeutics over months without surgical removal. |
| HQ Country | ||
| HQ City | Boston, MA | Los Angeles, CA |
| Deal Date | 7 Aug 2019 | 19 Jun 2019 |
| Valuation | $620M | $3M |
| EV/Revenue | ||
| EV/EBITDA | ||
This data is available for Pro users. Sign up to see all Glaukos acquisitions and their M&A valuation multiples. Start Free Trial | ||
Benchmark 350K+ Funding Rounds and Disclosed VC Valuation Multiples
Sign up to see data on 350K+ funding rounds and disclosed revenue and EBITDA valuation multiples, from seed, through growth stage, to pre-IPO.
Start Free TrialAbout Glaukos
| When was Glaukos founded? | Glaukos was founded in 1998. |
| Where is Glaukos headquartered? | Glaukos is headquartered in United States. |
| How many employees does Glaukos have? | As of today, Glaukos has over 1K employees. |
| Who is the CEO of Glaukos? | Glaukos' CEO is Thomas W. Burns. |
| Is Glaukos publicly listed? | Yes, Glaukos is a public company listed on NYSE. |
| What is the stock symbol of Glaukos? | Glaukos trades under GKOS ticker. |
| When did Glaukos go public? | Glaukos went public in 2015. |
| Who are competitors of Glaukos? | Glaukos main competitors include Demant, ICON plc, Baxter International, Pro Medicus, Masimo, Bruker, Bio-Rad Laboratories, Horiba, Insulet, Shimadzu. |
| What is the current market cap of Glaukos? | Glaukos' current market cap is $8B. |
| What is the current revenue of Glaukos? | Glaukos' last 12 months revenue is $553M. |
| What is the current revenue growth of Glaukos? | Glaukos revenue growth (NTM/LTM) is 25%. |
| What is the current EV/Revenue multiple of Glaukos? | Current revenue multiple of Glaukos is 14.8x. |
| Is Glaukos profitable? | No, Glaukos is not profitable. |
| What is the current EBITDA of Glaukos? | Glaukos has negative EBITDA and is not profitable. |
| What is Glaukos' EBITDA margin? | Glaukos' last 12 months EBITDA margin is (0%). |
| What is the current EV/EBITDA multiple of Glaukos? | Current EBITDA multiple of Glaukos is (9078.8x). |
| What is the current FCF of Glaukos? | Glaukos' last 12 months FCF is $27M. |
| What is Glaukos' FCF margin? | Glaukos' last 12 months FCF margin is 5%. |
| What is the current EV/FCF multiple of Glaukos? | Current FCF multiple of Glaukos is 300.3x. |
| How many companies Glaukos has acquired to date? | As of May 2026, Glaukos has acquired 2 companies. |
| What was the largest acquisition by Glaukos? | $620M acquisition of Avedro on 7th August 2019 was the largest M&A Glaukos has done to date. |
| What companies Glaukos acquired? | Glaukos acquired Avedro and DOSE Medical Corp.. |
| In how many companies Glaukos has invested to date? | Glaukos hasn't invested in any companies yet (or none have been disclosed publicly). |
See public comps similar to Glaukos
Lists including Glaukos
Start Your
Free Trial Today
Try Multiples for free for 3 days. Got questions or need a demo? Schedule a call with us below.
